A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Verastem, Inc.
National Cancer Institute (NCI)
Lumos Pharma
Incyte Corporation
AstraZeneca
iOnctura
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Peking University
Merck Sharp & Dohme LLC
Novartis
AstraZeneca
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Peptomyc S.L.
Daiichi Sankyo
Verastem, Inc.
Trishula Therapeutics, Inc.
Gruppo Oncologico del Nord-Ovest
Hummingbird Bioscience
Theriva Biologics SL
Phanes Therapeutics
Mayo Clinic
Trishula Therapeutics, Inc.
Immodulon Therapeutics Ltd
BioNTech SE
Taiho Pharmaceutical Co., Ltd.
OHSU Knight Cancer Institute
ETOP IBCSG Partners Foundation
Seagen Inc.
Nektar Therapeutics
Ludwig-Maximilians - University of Munich
iOMEDICO AG
Chinese PLA General Hospital
AstraZeneca
Halozyme Therapeutics
Incyte Corporation
Altor BioScience
Barts & The London NHS Trust
Universitaire Ziekenhuizen KU Leuven
Chinese PLA General Hospital
SCRI Development Innovations, LLC
Incyte Corporation
Icahn School of Medicine at Mount Sinai
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
University of California, San Francisco